Select a medication above to begin.
Zepbound
tirzepatide
Black Box Warnings .
Thyroid C-cell Tumor Risk
contraindicated in pts w/ medullary thyroid carcinoma (MTC) hx or family hx, or in pts w/ multiple endocrine neoplasia syndrome type 2 (MEN 2); dose-related and duration-dependent incr. in thyroid C-cell tumor incidence observed in rodents, but human relevance unknown; uncertain value of routine serum calcitonin or thyroid ultrasound monitoring; advise pts of potential MTC risk and thyroid tumor sx (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness)
Adult Dosing .
Dosage forms: INJ (pen): 2.5 mg per injection, 5 mg per injection, 7.5 mg per injection, 10 mg per injection, 12.5 mg per injection, 15 mg per injection; INJ (vial): 2.5 mg per 0.5 mL, 5 mg per 0.5 mL, 7.5 mg per 0.5 mL, 10 mg per 0.5 mL, 12.5 mg per 0.5 mL, 15 mg per 0.5 mL
weight management, chronic
- [5-15 mg SC qwk]
- Start: 2.5 mg SC qwk x4wk, then 5 mg SC qwk, then may incr. by 2.5 mg/wk no more frequently than q4wk; Max: 15 mg/wk; Info: for obese pts or overweight pts w/ wt-related comorbidity; recommended maint. dose is 5 mg, 10 mg, or 15 mg SC qwk
obstructive sleep apnea, moderate-severe
- [10-15 mg SC qwk]
- Start: 2.5 mg SC qwk x4wk, then 5 mg SC qwk, then incr. by 2.5 mg/wk no more frequently than q4wk; Max: 15 mg/wk; Info: for obese pts; recommended maint. dose is 10 mg or 15 mg SC qwk
renal dosing
- [see below]
- renal impairment: no adjustment
- HD/PD: not defined
hepatic dosing
- [no adjustment]
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.